LinkedIn Icon
September 18-20, 2018
Boston, MA

 

Speaker Faculty

Expand/Collapse

Julian Andreev
Senior Staff Scientist
Regeneron

Julian Andreev is a Ph.D. scientist with 16 years of experience in the Biopharmaceutical Industry. Right after his dissertation research in Dr. Joseph Schlessinger’s lab, he joined newly-formed Molecular Oncology group at EMD Serono Research Institute as Principal Investigator. At Serono, Julian played a major role into expansion of research activities into oncology drug discovery. Following his tenure at Sanofi Cambridge Research Center, Julian joined New York-based Regeneron Pharmaceuticals, where he established a research group studying mechanisms of intracellular trafficking of therapeutic antibodies and their targets. Julian Andreev received his B.Sc. in Biology and M.Sc. in Biotechnology from Hebrew University, Jerusalem. After training at Max-Planck Institute for Infection Biology in Tuebingen, Germany, he received his Ph.D. in Pharmacology from New York University, NY in 2000.

Day Two

Thursday, September 20

14.30 | Bispecific ADCs Bridging HER2 & Constitutively Internalizing Proteins Improve Efficacy Of HER2 ADCs

Edward Berger
Chief, Molecular Structure Section, Laboratory of Viral Diseases, NIAID
National Institutes of Health

Day Two

Thursday, September 20

11.30 | Bispecific CARs against HIV: Shared and Unique Challenges for HIV versus Cancer

John Burke
President, CEO & Co-Founder
Applied BioMath

Day One

Wednesday, September 19

09.30 | Model Aided Drug Invention (MADI) Case Studies in Research: In Silico Differentiation for Dual Targeting PD-1 and Tim-3 in I/O, and Predicting Optimal Drug Properties of a Bispecific Biologic to Maximize Tissue Targeting in OA

Christian Cimander
Associate Director,CMC,
Genmab

Day One

Wednesday, September 19

16.00 | Showcasing Effective CMC Development for Bispecific Antibodies

Jonathan Davis
Principal Scientist, Protein Design
Bristol-Myers Squib

Jonathan Davis received his Ph.D. from University of California, San Francisco, where he worked on protein structure and function. After a post-doc at Harvard Medical School studying RNA selection, structure, and function in the labs of Jack Szostak and Gerhard Wagner, he took a position in the New Technologies at EMD-Lexigen (now EMD Serono) in Billerica, MA. His work there involved improving antibody-based therapeutics, inventing a platform technology for generating heterodimeric Fcs as a basis for multifunctional molecules, and developing a novel scaffold based on an artificially-designed protein. He has extensive experience in selection technologies, library design, in silico modeling, and therapeutic discovery. In 2008 he moved to Adnexus, now Bristol-Myers Squibb, located in Waltham, MA, where he is a Principal Scientists in Molecular Structure and Design, working on projects ranging from improving optimization protocols to development of novel biotherapeutics.

John Desjarlais
CSO
Xencor

Dr. Desjarlais is the Senior Vice President, Research and Chief Scientific Officer at Xencor, Inc. Since joining Xencor in 2001, Dr. Desjarlais has overseen the company’s engineering work on antibodies and other proteins. With his coworkers, Dr. Desjarlais has developed several novel technologies for the optimization of antibodies and other proteins, including a platform for generation of bispecific antibodies, and has led the discovery of multiple novel antibody candidates for treatment of a variety of diseases. Dr. Desjarlais manages all of Xencor’s research activities, from project conception and candidate generation through preclinical proof of concept and early development. Prior to Xencor, Dr. Desjarlais was an Assistant Professor of Chemistry at Penn State University (1997-2001), where he developed and tested methods for the de novo design of protein sequences. He began his work in the field of protein design as a Jane Coffin Childs Fellow at U.C. Berkeley. Dr. Desjarlais holds a Ph.D. in Biophysics from the Johns Hopkins University and a B.S. degree in Physics from the University of Massachusetts, Amherst.

Day One

Wednesday, September 19

09:00  | Bispecific Technology for Multiple Avenues of T-Cell Activation

Rakesh Dixit
VP, Research & Development
MedImmune

Day One

Wednesday, September 19

08.30 | The Immune Force Awakens with Novel Bispecific Biotherapeutics

Pierre-Emmanuel Gerard
CEO
Biomunex

Day One

Wednesday, September 19

18.00 | Panel Discussion: Analysing Deal Structures and their Impact on the Bispecific Space

Matthias Friedrich
Scientific Director
Amgen

Changshou Gao
Senior Director & Fellow
MedImmune

Day Two

Thursday, September 20

13.00 | Modulating Bispecific Epitopes & Affinities to Enhance Safety and Efficacy

Dragan Grabulovski
CEO & Founder
Grabulovski Consulting Services

Afternoon Workshops

Tuesday September 18

13.00 | Workshop D: Bioanalytical Strategy for Bispecifics: Beyond Classical PK & Immunogenicity Assessment

Day One

Wednesday, September 19

19.15 | Chair’s Closing Remarks

17.45 | Chair’s Welcome to the Focus Evening

Jijie Gu
Head of Target Validation, Immunology Research
AbbVie

Phil Hammond
Director, Therapeutics Preclinical Development
Zymeworks

Day One

Wednesday, September 19

15.30 | Rapid CMC Development of Different Formats of Bispecifics Using Traditional Up- and Down-Stream Methods

John Haurum
CEO
F-Star

John has over 15 years’ experience in building and leading biotech companies across discovery, development, financing and business development. He successfully managed several monoclonal, oligoclonal, and bispecific antibody products into clinical development, as well as managed and developed numerous collaborations with biopharmaceutical companies in the US, Europe, and Japan. Prior to joining F-star, John was VP Research, Biologics Products at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company. Previously, he was a cofounder and Chief Scientific Officer of Symphogen A/S, a Danish biotechnology company developing therapeutic antibody combinations. John holds an MD from University of Aarhus, Denmark and a D.Phil. in Immunology from the Institute of Molecular Medicine, University of Oxford, UK.

Day One

Wednesday, September 19

18.00 | Panel Discussion: Analysing Deal Structures and their Impact on the Bispecific Space

Daniel Hofmann
Scientist
BioNTech

Afternoon Workshops

Tuesday September 18

13.00 | Workshop C: Investigating Approaches to Enable the Patient’s Body to Synthesise Bispecific Constructs by Administering DNA or mRNA Encoding the Therapeutic

Wibke Lembke
Associate Director Development
Covagen

Afternoon Workshops

Tuesday September 18

13.00 | Workshop D: Bioanalytical Strategy for Bispecifics: Beyond Classical PK & Immunogenicity Assessment

David Poon
Executive Director, External Research & Development
Zymeworks

Day One

Wednesday, September 19

18.00 | Panel Discussion: Analysing Deal Structures and their Impact on the Bispecific Space

Krzysztof Masternak
Head of Biology
NovImmune

Paul Moore
VP, Cell Biology & Immunology
MacroGenics

Morning Workshops

Tuesday September 18

09.00 | Workshop B: Investigating Immune Modulation Through Bispecifics – How Can We Select Rational Designs?

Ercole Rao
Group Leader, Biologics Research, Engineered Protein Therapeutics,
Sanofi

Day Two

Thursday, September 20

11.00 | Pioneering a Novel Bispecific Format Enabling the Generation of Flexible Bi- and Trispecific Therapeutics

Janine Schuurman
Corporate VP, Research & Innovation
Genmab

Day One

Wednesday, September 19

17.00 | Chair’s Closing Remarks

08:20  | Chair’s Opening Remarks

Day Two

Thursday, September 20

15.30 | Chair’s Closing Remarks

08.50 | Chair’s Opening Remarks

Laura von Schantz
Senior Scientist
Alligator Bioscience

Day One

Wednesday, September 19

16.30 | Engineering Functional and Developable TNFR Superfamily Bispecific Antibodies

Eric Smith
Director
Regeneron

Laura Jeanbart
Research Project Leader, Biology
Molecular Partners

Day Two

Thursday, September 20

15.00 | Targeting and Modulating the Tumor Microenvironment with Multispecific DARPin® Therapeutics

Krzysztof Wicher
Director of Research
Ossianix

Morning Workshops

Tuesday September 18

09.00 | Workshop A: Blood-Brain Barrier Crossing Biologics: Current Status, Future Potential, & Challenges in Developing These Therapeutics?

Martin Bader
Head of Biochemical and Analytical Research
Roche

Andrea Stacey
Group Leader, Preclinical Biology
Immunocore

Mark Paris
Director, Translational Applications
Mitra Biotech

Petter Veiby
Senior Director, Biotherapeutics & IO Partnerships, New Ventures
Takeda

Day One

Wednesday, September 19

18.00 | Panel Discussion: Analysing Deal Structures and their Impact on the Bispecific Space

Tobias Speck
Researcher
National Center for Tumor Diseases

Cris Kamperschroer
Senior Principal Scientist
Pfizer

Day Two

Thursday, September 20

10.00 | Mitigating Cytokine-Related Toxicities Induced by CD3 Bispecifics

Eugene Zhukovsky
CSO
Biomunex

Day Two

Thursday, September 20

09.30 | Next-Generation Bi- and Multi-Specific Antibody Platform BiXAb® for the Immunotherapy of Cancer

Jonathan Lai
Associate Professor
Albert Einstein College of Medicine

Day Two

Thursday, September 20

09.00 | Bispecific Antibodies as Immunotherapies Against Emerging Viruses